BioPharma Dive - Latest News

Immunovant claims study success for immune disease drug but holds off on submission

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

Mar 19, 2025 - 17:02
 0
Immunovant claims study success for immune disease drug but holds off on submission

The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.

Read More

Tags:

Previous Article

Alfa Romeo To Reveal Next-Generation Stelvio SUV Later This Year

Next Article

Human medicines European public assessment report (EPAR): Namuscla, mexiletine h...

Related Posts

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

Solid says early data suggest ‘differentiated’ Duchenne...

Feb 18, 2025  0

2Seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M

2Seventy bio, Bluebird’s cell therapy spinout, sells to...

Mar 11, 2025  0

3 ways to accelerate development and de-risk cell and gene therapy manufacturing

3 ways to accelerate development and de-risk cell and g...

Mar 10, 2025  0